Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Oral Omadacycline in CABP
NCT04160260Phase 1Completed
- Sponsor
- Paratek Pharmaceuticals
- Start
- Nov 2019
- Primary completion
- Mar 2020
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of omadacycline in community-acquired bacterial pneumonia (CAP), sponsored by Paratek Pharmaceuticals. Primary endpoints: Log Geometric Mean Area Under the Concentration Versus Time Curve (AUC) From Time 0 to 48 Hours After Dosing (AUC[0-48]), Log Geometric Mean AUC From Time 0 to 24 Hours After Dosing (AUC[0-24]) and 4 more. Started Nov 2019; status: completed.
02
Drugs
omadacycline
03
Conditions
community-acquired bacterial pneumonia (CAP)
Beyond the preview
Go deeper on NCT04160260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04160260.